Canada-based GVI Clinical Development Solutions has formed a joint venture to conduct phase II and III trials in China.

GVI is joining with IRD Medicine, based in Guangzhou, China, to set up the CRO, called IRD-CDS. The CRO will conduct biopharm, diagnostic, medical device and nutraceutical phase II and III trials.

"[IRD’s] in-depth knowledge of the life science industry in China combined with our team's expertise in conducting global clinical trials makes for a strong partnership that is ready to meet the needs of clinical stage companies," said Jan-Ake Westin, president of GVI.